TABLE 1.
Epidermal allograft recipient demographics upon enrollment
| Patient | Sex | Donor* | Donor chimerism (%): | Age (years) | Days post-alloHCT | ||
|---|---|---|---|---|---|---|---|
| Lymphoid PB (CD3+) | Myeloid PB (CD33+) | Skin | |||||
| 1 | M | MSD | 100 | 100 | 16 | 11.4 | 2236 |
| 2 | M | MSD | 34 | 43 | 5 | 2.5 | 743 |
| 3 | M | MSD | 35 | 35 | 17 | 6.6 | 1207 |
| 4 | M | Maternal haplo | 100 | 100 | 18 | 4.4 | 245 |
| 5 | F | Sibling haplo | 100 | 100 | 18 | 9.5 | 483 |
| 6 | F | MSD | 32 | 24 | 13 | 7.9 | 1107 |
| 7 | F | MSD | 100 | 100 | ND | 15.4 | 3111 |
| 8 | F | MSD | 100 | 100 | ND | 23 | 3100 |
| Median: | 100% | 100% | 16.5% | 8.7 years | 1157 days | ||
| (IQR): | (34–100) | (37–100) | (11–18) | (5–14.4) | (548–2884) | ||
*
AlloHCT and epidermal graft
RDEB, recessive dystrophic epidermolysis bullosa; alloHCT, allogeneic hematopoietic cell transplantation; M, male; MSD, human leukocyte antigen-matched sibling donor; haplo, human leukocyte antigen haploidentical donor; F, female; ND, not done.